Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis ...
Q2 2026
Aug 10, 2026
Q1 2026
May 6, 2026
FY 2025
Mar 30, 2026
Q4 2025
Q3 2025
Nov 6, 2025
